Skip to content
Announcement:
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
Announcement:
Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma
Generative Biology®
The Generate Platform™
Pipeline
About Us
Careers
Media Center
Investors
Menu
Close
Generative Biology®
The Generate Platform™
Pipeline
About Us
Careers
Media Center
Investors
LinkedIn
X
YouTube
